Home Compare GSK.L vs LLY
Stock Comparison · Industry comparison · Drug Manufacturers - General

GSK vs Eli Lilly and Company: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Eli Lilly and Company carrying a narrow edge on profitability. GSK still leads on valuation and stability, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Profitability still does most of the heavy lifting in this comparison.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. GSK.L and LLY share the same industry classification.

For a similarity-based comparison, see how GSK and Eli Lilly and Company each position within their functional peer groups in AssetNext.

Peer-Relative Score
GSK.L
GSK plc
65
Peer-Score
Signal qualityHigh
vs
LLY
Eli Lilly and Company
68
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in profitability.

Dimension spread: GSK.L vs LLY Profitability 46 100 Stability 69 34 Valuation 80 44 Growth 71 88 GSK.L LLY
Gap Ranking
#1 Profitability +54
#2 Valuation +36
#3 Stability +35
#4 Growth +17
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for GSK.L and LLY Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer GSK.LLLY Relative valuation Structural strength

Eli Lilly and Company still looks cheaper, even though GSK plc remains structurally stronger.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
Both profiles are strong on profitability, but Eli Lilly and Company leads clearly.
Valuation
On valuation, the edge is clear — both rank well, but GSK plc sits noticeably higher.
Profitability — Dominant Gap
GSK.L
46
LLY
100
Gap+54in favour of LLY

The profitability lead is mainly driven by a 26-point operating margin advantage.

What keeps the gap from being one-sided

Absolute pricing still looks more supportive for GSK, with a forward P/E that is 11 turns lower there.

What this means for the comparison

Profitability is the clearest driver of the lead, with valuation adding further support — though valuation still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the GSK.L vs LLY comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how GSK.L and LLY each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.